NEPA is a new oral fixed-dose combination of 300 mg netupitant , a highly selective NK1 receptor antagonist ( RA ) and 0.50 mg palonosetron ( PALO ) , a pharmacologically and clinically distinct 5-HT3 RA , which targets dual antiemetic pathways .